Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Teams with Brazilian Partner on HPV Test Evaluation

NEW YORK (GenomeWeb News) – Trovagene today said that it will collaborate with the PIO XII Foundation in Brazil to evaluate the performance of the firm's urine-based molecular assay for HPV types associated with cervical lesions.

The goal of the study is to determine if the test could potentially replace Pap smears as a primary screening tool for cervical cancer risk within Brazil's healthcare system.

The PIO XII Foundation is affiliated with the Barretos Cancer Hospital, which will conduct the study on Trovagene's test. Further tersm of the alliance were not disclosed.

"This study can pave the way to make HPV screening broadly available to medically underserved patients in our region," Adhemar Longatto Filho, from the Laboratory of Medical Investigation at the University of Sao Paulo and principal investigator for the study at Barretos Cancer Hospital, said in a statement. "Our goal is to provide patients with non-invasive testing options to determine their HPV risk factor and significantly improve women's healthcare in Brazil."

Earlier this year San Diego-based Trovagene inked a deal with India's Strand Life Sciences, under which Strand licensed and agreed to validate Trovagene's HPV urine test and high-risk HPV DNA assay.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.